| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10910911 | Lung Cancer | 2014 | 37 Pages |
Abstract
The CIP2A-dependent pathway mediates the tumoricidal effects of erlotinib on NSCLC cells without EGFR mutations in vitro and in vivo. CIP2A may be a novel molecular target against NSCLC for future drug development.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Cheng-Yi Wang, Ting-Ting Chao, Fang-Yu Chang, Yen-Lin Chen, Yi-Ting Tsai, Hen-I Lin, Yuh-Chin T. Huang, Chung-Wai Shiau, Chong-Jen Yu, Kuen-Feng Chen,